povetacicept

Asset

Dual BAFF and APRIL antagonist fusion protein

Stage: Phase 3
Modality: Protein or enzyme
Target: Inflammation; 1
Indication: 1
Trial: 1
Developer

Indications

1

Immunoglobulin a nephropathy
Phase 3, Enrolling by invitation, NCT07807995, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains3
Owner and partners1
Trials1
Evidence for its targets3
Competitors3
Aging relevance1
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 7 Oct 2026, 1 source